Cited by 112Acute Kidney Injury ResearchCOVID-19 Clinical Research StudiesChronic Kidney Disease and Diabetes

Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications

Open access
Zahid, Umar, Ramachandran, Preethi, Spitalewitz, Samuel, Alasadi, Lutfi, Chakraborti, Abhishek, Azhar, Muhammad, Mikhalina, Galina, Sherazi, Andleeb +3 more·2020·American Journal of Nephrology

Abstract

Background: Although diffuse alveolar damage and respiratory failure are the key features of coronavirus disease 2019 (COVID-19), the involvement of other organs such as the kidney has also been reported. The reports of the incidence of acute kidney injury (AKI) in COVID-19 patients vary widely. In this study, we report our unique experience with AKI in COVID-19 patients in a low socioeconomic and predominantly ethnic minority group and provide its incidence, risk factors, and prognosis to expand the current understanding of this complication. Methods: In this single-center, retrospective cohort study, we analyzed the data of 469 COVID-19 patients admitted to the Brookdale University Hospital in Brooklyn, NY, from March 18 through April 23, 2020. Information regarding demographics, comorbidities, medications, clinical and laboratory data, and outcomes was collected from the electronic medical records. Both univariate and multivariate analyses were performed to determine the association of AKI with in-hospital mortality. Results: The median age was 66 years (interquartile range [IQR] 25–75; range 19–101 years), and 268 (57.14%) patients were male. Estimated glomerular filtration rate (eGFR) as determined by the Modification of Diet in Renal Disease Study Equation was low (<60 mL/min/1.73 m 2) in 207 (44.1%) patients. During hospitalization, 128 (27.3%) patients developed AKI, and the incidence was significantly higher in those patients presenting with a low eGFR (N = 81, 39.1%; p < 0.001). Male sex, hypertension, the use of angiotensin-converting enzyme inhibitors and non-steroidal anti-inflammatories, hemodynamic instability, mechanical ventilation, acute respiratory distress syndrome, and admission elevated ferritin, creatinine kinase, brain natriuretic peptide, and troponin 1 were identified as the risk factors for in-hospital AKI. Ninety-seven (28.45%) patients died in the non-AKI group versus 91 (71.1%) in the AKI group (p < 0.001). The Cox proportional hazard model after adjusting for age, gender, comorbidities, hemodynamic status, and PF ratio (arterial oxygen partial pressure [PaO 2]/fractional inspired oxygen [FiO 2]) determined that on admission, an elevated blood urea nitrogen (hazard ratio [HR]: 1.75; 95% confidence interval [CI] 1.23–2.48), a low eGFR (HR 1.43; CI 1.1–2.03), AKI stage 1 (HR 1.14; CI 0.64–2.03), AKI stage 2 (HR 1.86; CI 1.03–3.56), and AKI stage 3 (HR 2.1; CI 1.3–2.81) were independent risk factors for in-hospital mortality. Renal replacement therapy (RRT) did not improve survival in stage III AKI. Conclusion: AKI in our hospitalized COVID-19 patients was common and carried a high mortality, especially in patients with AKI stage 3. RRT did not improve survival. Policy changes and planning for this high incidence of AKI in COVID-19 patients and its associated high mortality are necessary at the local and national levels.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000511160

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • According to studies, the incidence of AKI ranges between 46 percent and 71 percent; however, most deaths occur within the AKI sample.

    “According to studies, the incidence of AKI ranges between 46 percent and 71 percent; however, most deaths occur within the AKI sample [87, 88].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 7

  1. Wang L, Li X, Chen H, Yan S, Li D, Li Y. Coro- navirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospi- talized patients from Wuhan, China. Am J Nephrol. 2020; 51(5): 343-8.
  2. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into tar- get cells. bioRxiv. 2020. Posted 2020 Jan 31.
  3. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019- nCov. bioRxiv. 2020.
  4. Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling P, et al. Acute kidney in- jury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020 Jul; 31(7): 1380-3.
  5. Vuille-dit-Bille RN, Camargo SM, Emmeneg- ger L, Sasse T, Kummer E, Jando J, et al. Hu- man intestine luminal ACE2 and amino acid transporter expression increased by ACE-in- hibitors. Amino Acids. 2015; 47: 693-705.
  6. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin convert- ing enzyme 2 (ACE2) in SARS coronavirus - induced lung injury. Nat Med. 2005; 11: 875-9.
  7. King L, Hinterland K, Dragan KL, Driver CR, Harris TG, Gwynn RC, et al. Community health profiles 2015. Brooklyn Community District 16: Brownsville. 2015; 40(59): 1-16.

Cited by

Sorted by citations

Authors
Zahid, U., Ramachandran, P., Spitalewitz, S., Alasadi, L., Chakraborti, A., Azhar, M., Mikhalina, G., Sherazi, A., Narh, J. T., Khattar, P., & Bedi, P.
Affiliations
  • Brookdale University Hospital and Medical Center (US)
  • Icahn School of Medicine at Mount Sinai (US)
Venue
American Journal of Nephrology
Publisher
S. Karger AG
Published
2020
Volume
51
Issue
10
Pages
786-796
ISSN
  • 0250-8095 (ISSN-L)
  • 1421-9670
OpenAlex
W3091187654
Cited by
112
References
17
Citations by year
2026: 5 · 2025: 7 · 2024: 10 · 2023: 18 · 2022: 27 · 2021: 42 · 2020: 3
FWCI
14.15
Type
journal article
Language
en
Open access
Locations
  • American Journal of Nephrology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
acute kidney injury, COVID-19 pandemic, risk factors, in-hospital mortality, low socioeconomic status, ethnic minority patients, acute respiratory distress syndrome, mechanical ventilation, ACE inhibitors, nonsteroidal anti-inflammatory drugs, ferritin, creatine kinase, brain natriuretic peptide, hospital policy, Brooklyn
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Ethnicity, Female, Hospitals, Urban, Humans, Male, Middle Aged, Minority Groups, New York City, Pneumonia, Viral, Prognosis, Retrospective Studies, Risk Factors, Socioeconomic Factors, Incidence, Survival Analysis, Treatment Outcome, Hospital Mortality, Renal Replacement Therapy, Coronavirus Infections, Young Adult, Policy, Acute Kidney Injury, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review